Exclusive: Cellares expands deal with Bristol Myers on preclinical CAR-T asset, eyes manufacturing expansion

Cellares has expanded its partnership deal with Bristol Myers Squibb to assist the Big Pharma in developing another unnamed preclinical CAR-T cell therapy via its cell therapy manufacturing platform, Cell Shuttle.

The South San Francisco company also has its eyes on long-term expansion, which includes new collaborations and new builds…
Click here to view original post